NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Thursday, October, 31st. The company reported $1.24 EPS for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.10. The firm had revenue of $605.30 million for the quarter, compared to analyst estimates of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The business's quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $1.05 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

6 brokers have issued 1 year price objectives for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' share price to reach $293.33 in the next year. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

News headlines about IDXX stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days. View News Stories for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Alibaba Group (BABA), Adobe (ADBE), Mastercard (MA), Home Depot (HD), Intuitive Surgical (ISRG), Walt Disney (DIS) and Micron Technology (MU).

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.24%), Welch & Forbes LLC (0.21%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), New York State Teachers Retirement System (0.17%), Howland Capital Management LLC (0.15%) and Davis R M Inc. (0.14%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Moody Lynn & Lieberson LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Davis R M Inc., Cribstone Capital Management LLC and State of Alaska Department of Revenue. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Assenagon Asset Management S.A., Mckinley Capital Management LLC Delaware, Johanson Financial Advisors Inc., Aurora Investment Managers LLC., Pensionfund DSM Netherlands, Chapman Investment Management LLC and Ambassador Advisors LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $278.64.

IDEXX Laboratories has a market capitalization of $23.90 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]